Investigating efficacy and safety of adjunctive therapy in Parkinson’s Disease patients
Parkinson’s Disease involves the loss of brain cells that produce dopamine, a messenger that sends information to the parts of the brain that control movement and coordination. Lower than normal levels of dopamine in the brain causes the symptoms of Parkinson’s, including muscle stiffness, resting tremor (uncontrollable shaking), and slowing of movements. Parkinson’s patients may have “on” periods where they are able to control their muscle movement, and “off” times when controlling these movements is harder. Levodopa is a medication used to help treat Parkinson’s by increasing dopamine levels in the brain. We are looking for participants who have these “on” and “off” periods, and who are on Levodopa and at least one other medication. We are looking at whether adding tozadenant, a drug that hasn’t been approved by the U.S. FDA, will help improve Parkinson’s symptoms.
Recruiting | parkinsons adjunctive therapy | Not Multisite
Assessing the safety and efficacy of Macitentan in patients with portopulmonary hypertension
Several drugs (blood vessel dilators), including macitentan, are currently approved for the treatment of pulmonary arterial hypertension (PAH) in many parts of the world. These drugs have significantly improved the outcome of the condition. However, none of these treatments have been evaluated in portopulmonary hypertension, a form of PAH caused by liver disease. The purpose of this study is to assess the safety and effectiveness of macitentan in portopulmonary hypertension by looking at several clinical indicators, including the pressures within the arteries of the lungs and a person’s capacity for exercise.
Recruiting | High Blood Pressure / Hypertension | Not Multisite
How does a stroke affect balance during walking?
<p>The purpose of this study is to understand how a stroke affects walking balance and why people post-stroke fall more frequently. Findings from this study could inform the design of rehabilitation interventions to improve post-stroke walking ability.</p><p><strong>We are looking for</strong> <strong>people who have had a stroke AND healthy adults who have not had a stroke. </strong>Participants will walk on a treadmill while experiencing trips that challenge balance, but a safety harness will be worn to prevent any falls.</p>
USC GeneScreen: The USC Alzheimer’s Prevention Registry
<p>Researchers at USC invite you, and your friends and family, to <u>enroll online</u> in USC GeneScreen, USC Alzheimer's Prevention Registry.</p><p>Alzheimer’s disease is a brain disease that affects memory, thinking, and behavior. It is a progressive brain disorder that causes severe memory loss over time, making it increasingly difficult for people to carry out daily activities. Alzheimer's disease impacts us all. </p><p> While valuable Alzheimer's research is being done every day to treat and prevent this disease, finding interested research participants remains an ongoing challenge. USC GeneScreen is a registry for people who are interested in participating in Alzheimer’s disease research studies at USC. By joining the registry, members are the first to hear about new and innovative studies that they may be eligible to participate in. </p>
BENFO-TEAM
The BenfoTeam Study is a multi-site clinical trial evaluating whether Benfotiamine, a form of vitamin B1, can help slow memory decline and support brain health in individuals with early Alzheimer's disease. Benfotiamine is thought to enhance brain energy metabolism and reduce biological changes linked to Alzheimer's, including inflammation and abnormal protein buildup. Early research has shown it to be safe, well-tolerated, and potentially beneficial for cognition and daily function.
Recruiting | Mild Cognitive Impairment (MCI) | Not Multisite
Join today! New study at USC tests effectiveness of newly approved drug to help people with eczema, called Atopic Dermatitis
Atopic Dermatitis is a form of eczema that causes dry, scaly, itchy skin. More than 3 million cases are reported in the U.S. each year. People with this skin condition often have problems with bacterial skin infections caused by a specific bacteria known as, Staph aureus, or just Staph. Patients with chronic eczema often use long-term topical or oral treatments to help control their symptoms. But using these medications over long periods of time can have side effects on the body. The purpose of this study is to test the effectiveness of the drug dupilumab (dupixent), which was recently approved by the Food and Drug Administration (FDA) to offer relief to patients who cannot control their eczema with commonly used topical medications.We want to find out how dupilumab affects the amount of bacteria on the skin and the immune system of the patients, and whether it might cause less side effects. Join us today if you are between 18-65 years old with chronic eczema (Atopic Dermatitis).
Powered by
SC CTSI